Innovation with a Unique Table-Integrated Architecture

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson (JNJ)'s next-generation soft tissue surgical robot system, OTTAVA, for De Novo marketing authorization. The approved OTTAVA features a unique structure with four robotic arms fully integrated under a standard surgical table, a first in the industry. This innovative unified architecture significantly reduces operating room footprint by approximately 30% to 50% compared to existing cart-based or boom-mounted robotic systems. This provides a new alternative for smaller hospitals that previously could not adopt robotic surgical equipment due to space constraints. When not in use, the robotic arms can be hidden under the surgical table, maximizing space utilization, and this 'invisible' design is expected to bring significant changes to the market.

Scope and Indications Based on Clinical Data

The FDA approval for OTTAVA covers a wide range of general surgical procedures in the upper abdomen, demonstrating high clinical utility. Key indications include Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, and appendectomy. This approval is primarily based on data from a Roux-en-Y gastric bypass clinical study presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) in 2026, which successfully met the primary safety and performance endpoints. Johnson & Johnson is also actively conducting clinical trials in the U.S. to expand indications, including inguinal hernia surgery.

Workflow Optimization Through Integration with a Digital Ecosystem

OTTAVA goes beyond simply providing hardware and is closely integrated with Johnson & Johnson's Polyphonic digital platform. This integration allows medical professionals to organically utilize real-time surgical data collection, educational guide programs, and recorded surgical video analysis systems. Furthermore, the surgical table and robotic arm movements are synchronized in real-time, providing automatic positioning, which maximizes the surgical workflow. This significantly shortens the learning curve for medical professionals, making it a powerful tool for hospitals to reduce the initial costs and time risks associated with introducing surgical robots.

Phased Launch Strategy and Challenge to a Dominant Market

Following the FDA approval of OTTAVA, Johnson & Johnson has adopted a controlled rollout strategy, targeting a limited number of customers in the U.S. rather than a large-scale launch. This is a strategic decision to ensure quality control during the initial installation process and to establish complete clinical confidence before gradually expanding into the global market. The global surgical robotics market is currently dominated by Intuitive Surgical (ISRG)'s da Vinci system, which holds approximately 80% market share, with Medtronic (MDT)'s Hugo RAS as a competitor. Johnson & Johnson's entry is expected to disrupt this oligopoly and further stimulate technological innovation in the global surgical robotics market, which is estimated to be worth between $7.6 billion and $18.4 billion.